Amplification of both MYCN and MDM2 has also been detected in alveolar rhabdomyosarcoma, a subtype of rhabdomyosarcoma, and is associated with the deletion of retinoblastoma protein 1.129. This evidence concerns the gene MDM2 and rhabdomyosarcoma.